From a Deadly Disease to a Manageable Chronic Disease, HIV/AIDS Remains a Challenge for Mankind
Shimiao Shao,Yiming Shao
DOI: https://doi.org/10.1097/im9.0000000000000121
2023-01-01
Infectious Microbes & Diseases
Abstract:Acquired immune deficiency syndrome (AIDS) is caused by human immunodeficiency virus (HIV), which was found by French scientists 40 years ago,1 2 years after AIDS was firstly reported by US scientists.2 The HIV/AIDS pandemic has spread to every country of the world with over 84 million infections and more than 40 million deaths since the start of the epidemic.3 According to Joint United Nations Programme on HIV/AIDS (UNAIDS), there are 38.4 million people living with HIV/AIDS (PLWHA) in 2021.4 In order to realize the Ending AIDS Plan by 2030, the UNAIDS made the intermediate target of less than 500,000 new HIV infections and 500,000 AIDS-related deaths in 2020.5 In the 2021 United Nations (UN) 75th General Assembly, the General Secretary reported that the 2020 target of Ending AIDS Plan was not reached,6 with 1.7 million HIV infections and 690,000 AIDS-related deaths in 2019.7 In order to bring the Ending AIDS Plan back on track, UNAIDS setup a higher goal of “95-95-95,” meaning the percentage for all PLWHA who know their HIV status, who have access to treatment and who are virally suppressed, respectively.5,6 There are still big gaps to reach the goal, since the above categories only reached 85%, 75% and 68%, respectively, in 2021.4 Therefore, HIV/AIDS remains to be one of the heaviest diseases burden and highest mortality among infectious diseases. Even in the peak of the COVID-19 pandemic in 2021, reported deaths from AIDS are 2.56 times that from COVID-19 in Africa.8 In order to further promote AIDS research and facilitate exchange among AIDS researchers, the Journal Infectious Microbes & Diseases launched a Special Issue on AIDS and organized a series of articles, aiming not only to expand basic knowledge on HIV virology, pathogenesis and treatment, but also to provide up-to-date information on epidemiology, prevention and control in China. With joint efforts of researchers, medical journals and health care practitioners, major breakthroughs will keep happening and hopefully HIV infections can be cured in the foreseeable future. HIV was first reported in China through imported HIV-contaminated blood products in 1985.9 Subsequent outbreaks of HIV infections among injection drug users, plasma donors and men-who-have-sex-with-men were identified over the following two decades.10 There were an estimated 1.053 million PLWHA in China by the end of 2020.11 In 2021, 60,154 new HIV cases were reported in China and 19,623 people died from AIDS-related diseases.12 According to a nationwide molecular epidemiological research study in 2012, there were over 11 HIV-1 subtypes and circulating recombinant forms (CRFs) in China, among which CRF07_BC (35.5%), CRF01_AE (27.6%), CRF08_BC (20.1%) and subtype B′ (9.6%) were the four dominant strains.13 Liu et al.14 revealed that CRF07_BC and CRF08_BC emerged in 1988 and 1990, following the previous introduction of the HIV-1 B strain from Southeast Asia and the C strain from north India. The CRF01_AE was first introduced into China in seven clusters in cross heterosexual groups visiting southeast Asian countries15 and later became the most prevalent strains for sexual transmission (44.54%) in China,16 especially among men-who-have-sex-with-men (57.36%).17 Given the diversity of the HIV-1 subtypes and their varied distribution, prevalence and transmission modes, it is crucial to build an HIV molecular transmission network among HIV-infected individuals, not only to infer dissemination relationships over greater geographic areas and longer periods, but also to identify potential transmission hotspots.18 By combining molecular networks with field epidemiological surveys and social network analysis, a comprehensive transmission network can be constructed, which can be used to formulate tailored intervention measures to prevent new HIV outbreaks.19 Besides numerous molecular epidemiological studies in China, an HIV molecular transmission network-based prevention and control plan has also been initiated by Chinese Center for Disease Control and Prevention, with two versions of Technical Guidelines released and pilot projects initiated over the past few years. A database of hundreds of thousands of HIV genetic sequences has been built, laying a foundation for using HIV molecular transmission networks to inform and guide the precise HIV intervention and prevention.18 The biggest progresses in AIDS research are the discovery of several dozens of anti-HIV drugs and scaling up of combination antiretroviral therapy (cART). Acquired immune deficiency syndrome has turned from the deadliest disease of “super cancer” into one of the manageable chronic diseases, such as hypertension and diabetes. The worldwide cART programs have saved millions of lives and significantly improved the life quality of tens of millions of PLWHA. Although cART is very effective for HIV/AIDS, there is still no cure for HIV/AIDS and the antiviral treatment has to be lifelong. This is due to the persistence of viral reservoirs as well as HIV integration into cell chromosomes. When cART is discontinued, viral loads will rise again.20 To date, HIV cure has only been achieved in a few cases of allogeneic hematopoietic stem cell transplantation from donors with homozygous delta32 deletion in the CCR5 gene, since CCR5 is the coreceptor for HIV entry.21,22 The recipient receiving transplantation of bone marrow with such CCR5 gene deletion becomes resistant to HIV infection. The probability to use hematopoietic stem cell transplantation for HIV cure is extremely low, since delta32 deletion only exists in less than 1% of the Caucasian population. It failed to become a generalizable HIV cure procedure also due to its substantial risks and cost.23,24 Nevertheless, the first HIV cure case had inspired the global research toward HIV cure. In most cases, the goal is to reach a functional cure without virus eradication, keeping long-term health status after discontinuing antiviral therapy. The commonly used methodology to eliminate latent viral reservoirs includes shock and kill as well as the opposite block and lock strategy. The former uses latent reversal agents to activate the latent virus and then kill activated HIV, while the latter permanently silences the latent virus and prevents it from reactivation and replication.25 The other HIV cure research approaches include immunotherapy with therapeutic vaccines, or immune modulators to boost anti-HIV-1 immunity while conducting cART,25 as well as using monoclonal anti-HIV1 neutralizing antibodies.8,26–28 The HIV Cure Research group of International AIDS Society regularly issues Research priorities for an HIV cure to guide international cure research activities.29 Another major challenge to cART is that HIV may develop resistance to antiretroviral drugs after prolonged treatment, rendering antiretroviral treatment ineffective and increasing the risk of immunodeficiency and death again for HIV-infected patients.30 Because there is no cure and no effective vaccines for HIV, development of national surveillance programs to monitor drug-resistant HIV strains and prevent their spreading are particularly important to sustain effectiveness of the current cART program. In the past decades, the activities of conducting HIV tests and providing free cART have increased drastically in China. In 2021, a total of 320 million HIV tests were carried out to facilitate HIV/AIDS early diagnosis. Among diagnosed PLWHA, 92.6% have received cART and 96.4% of the patients on cART achieved viral suppression.31 The HIV/AIDS control in China, a nation that holds over 18% of the global population32 and accounts for approximately 3% of the PLWHA, has made a lot of progresses on the road to achieving “95-95-95.” Challenges for future works remain, since AIDS-related deaths in China are still more than all other infectious diseases combined in 2021.12